60 Degrees Pharma signs exclusive Florida State University patent license for Australian chestnut extract supplement use

60 Degrees

60 Degrees

SXTP

0.00
  • 60 Degrees Pharmaceuticals Inc. signed an exclusive patent license agreement with Florida State University covering non-prescription uses of Australian Chestnut Extract as a botanical supplement.
  • The license enables the company to begin large-scale extraction and purification of castanospermine from Castanospermum australe seeds.
  • The company plans to meet the FDA on July 1, 2026, to discuss a Non-Notification Letter tied to its New Dietary Ingredient Notification filing and expects to submit a revised notification.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. 60 Degrees Pharmaceuticals Inc. published the original content used to generate this news brief on June 11, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.